Christopher Richard Anzalone Sells 12,586 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 12,586 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $68.44, for a total transaction of $861,385.84. Following the transaction, the chief executive officer directly owned 3,805,926 shares in the company, valued at $260,477,575.44. The trade was a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

• On Friday, December 19th, Christopher Richard Anzalone sold 13,445 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $67.66, for a total transaction of $909,688.70.
• On Wednesday, December 17th, Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $64.04, for a total transaction of $5,443,400.00.
• On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $62.58, for a total value of $3,397,968.84.
• On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $68.85, for a total value of $8,950,500.00.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $70.50 on Thursday. The business’s fifty day simple moving average is $50.46 and its 200 day simple moving average is $32.32. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $72.36. The firm has a market capitalization of $9.58 billion, a P/E ratio of -881.13 and a beta of 1.28.

Arrowhead Pharmaceuticals News Summary

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Company-scheduled investor activity in early January could be a near-term catalyst: a KOL webinar on Jan 6 that will present interim clinical data for obesity programs ARO‑INHBE and ARO‑ALK7, and a corporate presentation at the J.P. Morgan Healthcare Conference the week of Jan 12. Positive interim data or a well-received JPM presentation could lift sentiment. Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
• Positive Sentiment: Analysts have been raising targets in December (multiple banks increased price objectives and reiterated buy/outperform views), which supports positive investor sentiment and can underpin higher trading levels heading into data/events.
• Neutral Sentiment: Short-interest reporting in late December shows anomalous/zero values in the public feed (appears to be a data error), so short-interest signals are currently unreliable for gauging downside pressure. Investors should watch for corrected exchange reports.
• Negative Sentiment: Multiple insiders sold shares in late December — including CEO Christopher Anzalone and several directors — disclosed in SEC Form 4 filings. While the CEO still holds a large stake and the percentage reductions were modest, clustered insider sales can be viewed negatively by some market participants. See SEC filings for details: CEO Form 4 CEO Form 4, Director filings and trade disclosures Director Form 4 Director Form 4 and a trade summary on InsiderTrades for one director InsiderTrades Waddill Sale.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ARWR shares. Bank of America raised their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. HC Wainwright raised their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Royal Bank Of Canada lifted their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Morgan Stanley increased their price objective on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a report on Wednesday, November 26th. Finally, Piper Sandler raised their target price on Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $61.89.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth $29,000. Salomon & Ludwin LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at $34,000. Federated Hermes Inc. purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth about $52,000. Smartleaf Asset Management LLC boosted its stake in Arrowhead Pharmaceuticals by 2,186.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,618 shares during the period. Finally, Virtus Advisers LLC bought a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth about $34,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.